FLT3 and graft versus host disease: When stratified according to FLT3‐ITD mutation status (Table S7), patients harboring the mutation with MRD positivity at transplant had higher acute II–IV (32.8% vs. 24.8%, p = 0.005) and III–IV (11.8% vs. 7.4%, p = 0.02) GVHD and RI (38.7% vs. 22%, p = 0.001) with lower LFS (46.9% vs. 63%, p = 0.001), OS (55.8% vs. 70.3%, p = 0.001), and GRFS (36.7% vs. 51.7%, p = 0.001).